* Xenetic Biosciences will acquire privately held Santersus in an all-stock share exchange, subject to shareholder approval. * The combined company is expected to remain Nasdaq-listed as Santersus Bio under ticker SNTS. * The deal combines Santersus’ NucleoCapture blood purification platform with Xenetic’s DNase technology, both aimed at neutrophil extracellular traps. * The pipeline includes pivotal-stage sepsis and systemic lupus erythematosus programs, each holding FDA Breakthrough Device Designation. * Leadership is expected to shift to Santersus CEO James Ladtkow, with Xenetic interim CEO and CFO James Parslow continuing in management.
XBIO•XBIO•XBIO•XBIO•
